Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SHR-1703 SAD Study in Healthy Subjects
NCT04480762Phase 1Completed
- Sponsor
- Hengrui
- Start
- Aug 2020
- Primary completion
- Sep 2021
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of SHR-1703 in asthma (5 arms), sponsored by Hengrui. Primary endpoints: Adverse events and serious adverse events, Safety as determined by abnormality in haematology and 7 more. Started Aug 2020; status: completed.
02
Drugs
SHR-1703
03
Conditions
asthma
Beyond the preview
Go deeper on NCT04480762.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04480762.